Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2020

09.01.2020 | short review

Importance of avoiding late cancer-directed therapy in terminally ill cancer patients

verfasst von: Dr. Daniela Jahn-Kuch, MSc

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Summary

It is undeniably a great challenge to adequately weigh the benefits and harms of tumor-specific therapy near the end of life and to find the right time for changing the objective of therapy to palliative care alone. In a curative situation, the “survival” benefit of the treatment outweighs its potential harm due to side effects. However, things are different when the possibility of cure is ruled out. Important prerequisites to avoid overly zealous care are adequate communication about the therapeutic options and consensus between the doctor and the patient with regard to the (realistic) therapeutic goal, a realistic estimated prognosis and early integration of palliative care.
Literatur
1.
Zurück zum Zitat Henson LA, Gomes B, Koffman J, Daveson BA, Higginson IJ, Gao W, et al. Factors associated with aggressive end of life cancer care. Support Care Cancer. 2016;24(3):1079–89.CrossRef Henson LA, Gomes B, Koffman J, Daveson BA, Higginson IJ, Gao W, et al. Factors associated with aggressive end of life cancer care. Support Care Cancer. 2016;24(3):1079–89.CrossRef
2.
Zurück zum Zitat Martoni AA, Tanneberger S, Mutri V. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori. 2007;93(5):417–22.CrossRef Martoni AA, Tanneberger S, Mutri V. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori. 2007;93(5):417–22.CrossRef
3.
Zurück zum Zitat Goncalves JF, Goyanes C. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer. 2008;16(4):321–7.CrossRef Goncalves JF, Goyanes C. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer. 2008;16(4):321–7.CrossRef
4.
Zurück zum Zitat Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol. 2011;22(11):2375–80.CrossRef Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol. 2011;22(11):2375–80.CrossRef
5.
Zurück zum Zitat Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138(8):639–43.CrossRef Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138(8):639–43.CrossRef
6.
Zurück zum Zitat Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–21.CrossRef Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–21.CrossRef
7.
Zurück zum Zitat Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24(21):3490–6.CrossRef Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24(21):3490–6.CrossRef
8.
Zurück zum Zitat Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care. 2011;10:14.CrossRef Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care. 2011;10:14.CrossRef
9.
Zurück zum Zitat Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219.CrossRef Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219.CrossRef
10.
Zurück zum Zitat Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, et al. Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol. 2008;38(5):381–6.CrossRef Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, et al. Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol. 2008;38(5):381–6.CrossRef
11.
Zurück zum Zitat Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778–84.CrossRef Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778–84.CrossRef
12.
Zurück zum Zitat Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.CrossRef Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.CrossRef
13.
Zurück zum Zitat van Oorschot B. Krebs im Endstadium: Überengagierte Versorgung am Lebensende. Dtsch Arztebl Int. 2018;115(47):16. van Oorschot B. Krebs im Endstadium: Überengagierte Versorgung am Lebensende. Dtsch Arztebl Int. 2018;115(47):16.
14.
Zurück zum Zitat Enzinger AC, Zhang B, Schrag D, Prigerson HG. Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. J Clin Oncol. 2015;33(32):3809–16.CrossRef Enzinger AC, Zhang B, Schrag D, Prigerson HG. Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. J Clin Oncol. 2015;33(32):3809–16.CrossRef
15.
Zurück zum Zitat Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327(7408):195–8.CrossRef Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327(7408):195–8.CrossRef
16.
Zurück zum Zitat Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320(7233):469–72.CrossRef Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320(7233):469–72.CrossRef
17.
Zurück zum Zitat Stone PC, Lund S. Predicting prognosis in patients with advanced cancer. Ann Oncol. 2007;18(6):971–6.CrossRef Stone PC, Lund S. Predicting prognosis in patients with advanced cancer. Ann Oncol. 2007;18(6):971–6.CrossRef
18.
Zurück zum Zitat Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L, et al. Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Support Palliat Care. 2015;5(4):390–8.CrossRef Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L, et al. Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Support Palliat Care. 2015;5(4):390–8.CrossRef
19.
Zurück zum Zitat Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–25.CrossRef Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–25.CrossRef
20.
Zurück zum Zitat Bluhm M, Connell CM, De Vries RG, Janz NK, Bickel KE, Silveira MJ. Paradox of prescribing late chemotherapy: oncologists explain. J Oncol Pract. 2016;12(12):e1006–e15.CrossRef Bluhm M, Connell CM, De Vries RG, Janz NK, Bickel KE, Silveira MJ. Paradox of prescribing late chemotherapy: oncologists explain. J Oncol Pract. 2016;12(12):e1006–e15.CrossRef
21.
Zurück zum Zitat Epstein AS, Prigerson HG, O’Reilly EM, Maciejewski PK. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol. 2016;34(20):2398–403.CrossRef Epstein AS, Prigerson HG, O’Reilly EM, Maciejewski PK. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol. 2016;34(20):2398–403.CrossRef
22.
Zurück zum Zitat Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010;28(7):1203–8.CrossRef Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010;28(7):1203–8.CrossRef
23.
Zurück zum Zitat Barclay JS, Kuchibhatla M, Tulsky JA, Johnson KS. Association of hospice patients’ income and care level with place of death. JAMA Intern Med. 2013;173(6):450–6.CrossRef Barclay JS, Kuchibhatla M, Tulsky JA, Johnson KS. Association of hospice patients’ income and care level with place of death. JAMA Intern Med. 2013;173(6):450–6.CrossRef
24.
Zurück zum Zitat Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers’ mental health. J Clin Oncol. 2010;28(29):4457–64.CrossRef Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers’ mental health. J Clin Oncol. 2010;28(29):4457–64.CrossRef
25.
Zurück zum Zitat Smith CB, Phillips T, Smith TJ. Using the new ASCO clinical practice guideline for palliative care concurrent with oncology care using the TEAM approach. Am Soc Clin Oncol Educ Book. 2017;37:714–23.CrossRef Smith CB, Phillips T, Smith TJ. Using the new ASCO clinical practice guideline for palliative care concurrent with oncology care using the TEAM approach. Am Soc Clin Oncol Educ Book. 2017;37:714–23.CrossRef
26.
Zurück zum Zitat Bakitas MA, El-Jawahri A, Farquhar M, Ferrell B, Grudzen C, Higginson I, et al. The TEAM approach to improving oncology outcomes by incorporating palliative care in practice. J Oncol Pract. 2017;13(9):557–66.CrossRef Bakitas MA, El-Jawahri A, Farquhar M, Ferrell B, Grudzen C, Higginson I, et al. The TEAM approach to improving oncology outcomes by incorporating palliative care in practice. J Oncol Pract. 2017;13(9):557–66.CrossRef
Metadaten
Titel
Importance of avoiding late cancer-directed therapy in terminally ill cancer patients
verfasst von
Dr. Daniela Jahn-Kuch, MSc
Publikationsdatum
09.01.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00564-1

Weitere Artikel der Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020 Zur Ausgabe